Luca Boni

Ospedale Policlinico San Martino — Italy

Medicine · Health Sciences

58h-index14.6kcitations515works4.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Colorectal Cancer Treatments and Studies(97), Lung Cancer Treatments and Mutations(64), Estrogen and related hormone effects(61), Cancer Treatment and Pharmacology(54), Breast Cancer Treatment Studies(49)

Publications512 total

Validation of PREDICT tool v2.2 in patients with early-stage breast cancer enrolled in the GIM and MIG trials
ESMO Open·2026Open Access
Endovascular vs conservative treatment in patients with chronic subdural hematomas and mild symptoms: a study protocol for a multicenter randomized controlled trial (EMBOTRIAL-1)
Trials·2025Open Access
Re-treatment with panitumumab followed by regorafenib versus the reverse sequence in chemorefractory metastatic colorectal cancer patients with RAS and BRAF wild-type circulating tumor DNA: the PARERE study by GONO
Annals of Oncology·2025· 4 citedOpen Access
Weight Changes during Early Breast Cancer Treatment and Their Association with Survival: An Exploratory Functional Data Analysis of GIM-2 Trial
Epidemiology Biostatistics and Public Health·2025Open Access
572P Molecular imaging with 18F-fluoroestradiol (18F-FES) to assess intrapatient heterogeneity in ER+/HER2- metastatic breast cancer (MBC) treated with first-line endocrine therapy: Final results of the ET-FES trial
Annals of Oncology·2025
1732TiP A phase II, multicenter, single-arm trial of durvalumab with carboplatin plus etoposide followed by durvalumab in patients with metastatic pulmonary large-cell neuroendocrine carcinoma (LCNEC) – DUPLE study – GOIRC-05-2020
Annals of Oncology·2025
LBA32 Panitumumab retreatment followed by regorafenib versus the reverse sequence in chemorefractory metastatic colorectal cancer patients with RAS and BRAF wild-type circulating tumor DNA (ctDNA): Final results of the randomized PARERE trial by GONO
Annals of Oncology·2025Open Access
223MO Phase II study of short-course radiotherapy (SCRT) followed by consolidation chemotherapy with FOLFOXIRI as total neoadjuvant therapy (TNT) for locally advanced rectal cancer (LARC) patients (pts): The ShorTrip study
Annals of Oncology·2025Open Access
Abstract P3-12-18: NEOMET: A phase II randomized trial to evaluate the impact of “targeted” nutritional support and exercise on modulation of metabolic and immune-related markers in early breast cancer (eBC) patients candidate to neoadjuvant therapy (NAT)
Clinical Cancer Research·2025
Abstract GS1-08: Association between risk-reducing surgeries and survival in young BRCA carriers with breast cancer: results from an international cohort study
Clinical Cancer Research·2025· 1 cited
Abstract P2-11-09: Adding Carboplatin to neoadjuvant chemotherapy (NACT) in early triple-negative breast cancer (eTNBC): a systematic review and meta-analysis
Clinical Cancer Research·2025
Barriers and Facilitators in Diagnostic Pathways That Align Universal Tumor Screening and Mainstream Genetic Testing for Lynch Syndrome in Colorectal Cancer: Protocol for a Scoping Review With a Narrative Synthesis
JMIR Research Protocols·2025· 1 citedOpen Access
Panitumumab retreatment followed by regorafenib versus the reverse sequence in chemorefractory metastatic colorectal cancer patients with <i>RAS</i> and <i>BRAF</i> wild-type circulating tumor DNA (ctDNA): Results of the phase II randomized PARERE trial by GONO.
Journal of Clinical Oncology·2025· 3 cited
Alectinib as neoadjuvant treatment in potentially resectable stage III ALK-positive NSCLC: Final analysis of ALNEO phase II trial (GOIRC-01-2020-ML42316).
Journal of Clinical Oncology·2025· 6 cited
Phase II study of short-course radiotherapy (SCRT) followed by consolidation chemotherapy with FOLFOXIRI as total neoadjuvant therapy (TNT) for locally advanced rectal cancer (LARC) patients (pts): The ShorTrip study.
Journal of Clinical Oncology·2025
Mainstreaming the diagnosis of Lynch syndrome (LS) in colorectal cancer (CRC) patients: The ItaLynch study.
Journal of Clinical Oncology·2025
Upfront modified FOLFOXIRI plus panitumumab (pan) versus FOLFOX/pan for unresectable <i>RAS</i> and <i>BRAF</i> wild-type (wt) metastatic colorectal cancer (mCRC) patients: Overall survival (OS) results from the phase III TRIPLETE study by GONO.
Journal of Clinical Oncology·2025· 4 cited
Supplementary Figure S2 from Predictive Effect of IGFBP-3 on Low-Dose Tamoxifen Efficacy in Noninvasive Breast Cancer in the Phase III Tam-01 Trial
2025Open Access
Supplementary Figure S3 from Predictive Effect of IGFBP-3 on Low-Dose Tamoxifen Efficacy in Noninvasive Breast Cancer in the Phase III Tam-01 Trial
2025Open Access
Supplementary Table S4 from Predictive Effect of IGFBP-3 on Low-Dose Tamoxifen Efficacy in Noninvasive Breast Cancer in the Phase III Tam-01 Trial
2025Open Access
page 1 of 26Next →

Frequent Co-authors

Sara Lonardi(14), Chiara Cremolini(12), Alfredo Falcone(11), Gianluca Masi(10), Alberto Zaniboni(8), Giuseppe Tonini(8), Paolo Bruzzi(8), Fotios Loupakis(7), Carlotta Antoniotti(7), Monica Ronzoni(7), Gabriella Fontanini(7), Lisa Salvatore(7), Angela Buonadonna(7), Federica Marmorino(7), Giuseppe Aprile(7), Giacomo Allegrini(6), Cristina Granetto(6), Andrea Ardizzoni(6), Francesca Bergamo(6), Bruno De Bernardi(6)